P2X4 receptor controls microglia activation and favors remyelination in autoimmune encephalitis (2018)

Peer-Reviewed Study · Zabala A, Vazquez-Villoldo N, Rissiek B, Gejo J, Martin A, Palomino A, et al. · August 2018

Zabala A et al., 2018-08: Mouse study in which ivermectin, acting as a P2X4 receptor modulator, pushed microglia to an anti-inflammatory state and improved remyelination and clinical signs in the EAE model of multiple sclerosis.

potentiation of P2X4R signaling by the allosteric modulator ivermectin (IVM) favored a switch in microglia to an anti-inflammatory phenotype, potentiated myelin phagocytosis, promoted the remyelination response, and ameliorated clinical signs of EAE

Zabala A et al., 2018-08: Mouse study in which ivermectin, acting as a P2X4 receptor modulator, pushed microglia to an anti-inflammatory state and improved remyelination and clinical signs in the EAE model of multiple sclerosis. Animal and cell study (EAE mouse model, microglia and oligodendrocyte cultures), no human subjects; Spain (Achucarro Basque Center for Neuroscience) with German co-authors. Ivermectin used as a P2X4 positive allosteric modulator, not as an antiparasitic; dose not stated in the abstract. No funding or conflict statement in the PubMed record. This is the primary research behind the NaturalNews piece (IVE-66) , the article's quoted phrase 'a potential candidate among currently used drugs to promote myelin repair' is the closing sentence of this abstract. Evidence level: animal model only; no human MS trial. This is the mouse study described in the August 2025 NaturalNews article. Also filed as IVA-54 (claims C12, C7). Study type: animal.